| Literature DB >> 33352759 |
Ahmad Joshkon1,2, Xavier Heim1,3, Cléa Dubrou1, Richard Bachelier1, Wael Traboulsi1, Jimmy Stalin1, Hussein Fayyad-Kazan2, Bassam Badran2, Alexandrine Foucault-Bertaud1, Aurelie S Leroyer1, Nathalie Bardin1,3, Marcel Blot-Chabaud1.
Abstract
The fundamental role of cell adhesion molecules in mediating various biological processes as angiogenesis has been well-documented. CD146, an adhesion molecule of the immunoglobulin superfamily, and its soluble form, constitute major players in both physiological and pathological angiogenesis. A growing body of evidence shows soluble CD146 to be significantly elevated in the serum or interstitial fluid of patients with pathologies related to deregulated angiogenesis, as autoimmune diseases, obstetric and ocular pathologies, and cancers. To block the undesirable effects of this molecule, therapeutic antibodies have been developed. Herein, we review the multifaceted functions of CD146 in physiological and pathological angiogenesis and summarize the interest of using monoclonal antibodies for therapeutic purposes.Entities:
Keywords: CD146; angiogenesis; cancer; endothelial cell; inflammation; monoclonal antibodies
Year: 2020 PMID: 33352759 PMCID: PMC7767164 DOI: 10.3390/biomedicines8120633
Source DB: PubMed Journal: Biomedicines ISSN: 2227-9059